Highlights and Quick Summary
- Total liabilities for the quarter ending September 30, 2022 was $801 Million (a 10.71% increase compared to previous quarter)
- Year-over-year quarterly Total liabilities increased by 15.27%
- Annual Total liabilities for 2021 was $695 Million (a 96.38% increase from previous year)
- Annual Total liabilities for 2020 was $354 Million (a 158.32% increase from previous year)
- Annual Total liabilities for 2019 was $137 Million (a 40.39% increase from previous year)
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Total liabilities of BioCryst Pharmaceuticals, Inc.
Most recent Total liabilitiesof BCRX including historical data for past 10 years.Interactive Chart of Total liabilities of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Total liabilities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $801.25 | $723.77 | $691.94 | – |
| 2021 | $695.14 | $412.81 | $383.36 | $359.42 | $695.14 |
| 2020 | $353.98 | $142.59 | $138.2 | $132.94 | $353.98 |
| 2019 | $137.03 | $131.75 | $125.54 | $119.83 | $137.03 |
| 2018 | $97.61 | $95.44 | $90.46 | $93.32 | $97.61 |
| 2017 | $94.49 | $90.86 | $89.43 | $90.98 | $94.49 |
| 2016 | $88.27 | $87.51 | $68.83 | $75.08 | $88.27 |
| 2015 | $74.64 | $74.91 | $74.09 | $65.5 | $74.64 |
| 2014 | $61.24 | $53.67 | $51.89 | $49.11 | $61.24 |
| 2013 | $49.99 | $49.8 | $48.96 | $49.74 | $49.99 |
| 2012 | $57.89 | $54.31 | $60.58 | $56.94 | $57.89 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology